Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "IDA"

1727 News Found

P. D. Hinduja Hospital spreads solidarity for cancer awareness
Healthcare | February 07, 2025

P. D. Hinduja Hospital spreads solidarity for cancer awareness

Cancer cases in India estimated to reach 1.57 million in 2025


Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr
News | February 06, 2025

Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr

Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL


Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr
News | February 06, 2025

Hikal Q3 FY25 consolidated revenue recorded at Rs. 448 Cr

The stable raw materials prices, focused cost improvement initiatives and intensified customer acquisitions helped the company to improve its margin profile


Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25
News | February 04, 2025

Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25

EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore


Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr
News | January 28, 2025

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024


Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
News | January 28, 2025

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024


AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma
News | January 17, 2025

AbbVie partners with Simcere Zaiming to develop Novel Trispecific Antibody Candidate in Multiple Myeloma

SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3


Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease
Drug Approval | January 07, 2025

Sentynl Therapeutics receives USFDA acceptance and priority review of new drug application for CUTX-101 product candidate for treatment of Menkes disease

Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A


Lonza outlines strategy, new organizational structure and guidance
News | December 12, 2024

Lonza outlines strategy, new organizational structure and guidance

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities